Member Info for Taff8

Seres up570% wakey wakey 4D mkt cap £80m,seres $2.5b mkt cap atm

Imac1, would say 4d has more potential from here than sng and Tils, with mkt cap only £80m,no brainer it sit and wait for 5bgs easy.

Seres mkt cap $1.45b
4D £80m

Imac1, same here sold@198,was in tils@47p but sold for peanuts, not goi g to sell here u der £2min.

Sees up335% $1b mkt cap, wakey wakey everyone

The big boys will start buying no brainer from here, potential $1b licence deal with Merck aswel.

Was in sng@35 did my research and new the drug worked as it already been proven elsewhere, exactly some boat here in@62p and happy to hold until £3 min.

Oncology (MRx0518)
4D’s MRx0518 is a live biotherapeutic candidate for cancer. We are investigating the effects of this candidate in a wide range of solid tumour types.

Phase I/II combination study
In collaboration with Merck & Co., known as MSD outside the United States and Canada, we are conducting a Phase I/II investigation of the combination of MRx0518 and Keytruda (pembrolizumab) in patients who with advanced and/or metastatic non-small cell lung cancer, kidney cancer, bladder cancer or melanoma who have failed prior anti-PD-1 therapy. This study is taking place in the United States.

Details of the study can be found here.

In 2016 $MCRB had a 'bad' Phase II Clinical Trial result on their c.difficile product. Today they've had positive news on a Phase III trial on the same indication.

2016 'Fail' led to huge de-rating of the entire Microbiome sector. Today's news should see MAJOR re-rating #DDDD

Mickle, have a look at PDSB aswell tiny mkt cap huge potential, covid19 vaccine play with 2 vaccines, also in bed with Merck.

Series up 300% pre market valued close to $1b,4d £80m mmmmmm

Waiting for the potential $1b Merck license deal, us covid19 treatment phase 2 trials, dyor don't miss out

Did you miss ncyt, sng and Tils?? Here's you chance gl

Jiddy, pdsb has mke cap $70m so 7%=$4.9m/£4.2m,not in nsci but I'm in pdsb@3.75.

Barry Clare, Executive Chairman of Evgen, said: ''We are delighted to be supporting Dundee University in this trial which we fervently hope will lead to an additional treatment for COVID-19 patients. We are excited that, as a proven activator of the Nrf2 pathway, SFX-01 could be of significance in the COVID-19 pandemic.''

Phase 2 development results due

Here we go first stop 10p

Market waking up finally

And up she goes worth multiple mkt cap and royalties from major mkt cap £9m,no brainer

Seller out all clear to 12p